相关实验视频
Updated: Jun 23, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
自动化胰岛素输送系统:一种适度至高风险斋月禁食的解决方案,适用于1型糖尿病患者
Cécilia Outenah1, Khadijatou Ly Sall1, Alfred Penfornis1,2
1Diabetology Department, Centre Hopitalier Sud Francilien, Corbeil-Essonnes, France.
Diabetes technology & therapeutics
|June 18, 2024
概括
在使用混合闭环 (HCL) 治疗的1型糖尿病患者中,斋月禁食并没有破坏代谢控制. 持续的葡萄糖监测显示,在宗教仪式期间,时间范围稳定,没有严重事件.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 糖尿病 技术 技术
背景情况:
- 研究了斋月禁食对使用混合闭环胰岛素治疗的1型糖尿病 (T1D) 患者代谢控制的影响.
- 一项前性研究,涉及20名T1D患者,基线风险中度至高.
- 比较了斋月前一个月和斋月期间的持续血糖监测 (CGM) 数据.
研究的目的:
- 为了评估斋月禁食是否会在接受HCL治疗的T1D患者中挑战新陈代谢控制.
- 为了比较斋月前和斋月期间的持续血糖监测 (CGM) 参数.
主要方法:
- 对20名中度至高基线风险的T1D患者进行前性实践研究.
- CGM数据的比较 (TIR,时间低于范围) 在斋月前一个月和斋月期间.
- 对HCL系统使用情况和急性代谢事件的分析.
主要成果:
- 在斋月期间 (63%) 与之前 (62%) 的时间里程 (TIR) 没有显著差异.
- 观察到稳定的血糖控制,低血糖没有增加 (时间<70 mg/dL).
- 维持高HCL系统使用 (93-94%),没有报告急性代谢事件.
结论:
- 在使用HCL治疗的T1D患者中,斋月禁食不会对代谢控制产生负面影响.
- 在宗教禁食期间,HCL系统在维持血糖目标方面表现出强大.
- 在不同基线风险概况中,研究结果一致.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Insulin Formulations: Types and Delivery
188
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
188
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Insulin: Biosynthesis, Chemistry, and Preparation
372
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
372
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316

